Download PDF
Nephrologie aktuell 2025; 29(04): 170-182
DOI: 10.1055/a-2511-0573
Schwerpunkt
CME-Fortbildung

Aktueller Stand der Therapie der renalen Anämie mittels HIF-Stabilisation

Thilo Krüger
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Die renale Anämie ist eine häufige Begleiterkrankung bei Patienten mit fortgeschrittener chronischer Niereninsuffizienz (CKD: „chronic kidney disease“). Dies führt so weit, dass im Stadium der Dialysepflicht etwa 80 % der Patienten von dieser Begleiterkrankung betroffen sind und in der Regel eine spezifische Therapie notwendig ist. Der folgende Beitrag beleuchtet neue Therapieoptionen und diskutiert Pro und Contra auf Basis der entsprechenden Studien.



Publication History

Article published online:
21 May 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Singh AK, Szczech L, Tang KL. et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med 2006; 355: 2085-2098
    CrossrefPubMedSearch in Google Scholar
  • 2 Drüeke TB, Locatelli F, Clyne N. et al. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med 2006; 355: 2071-2084
    CrossrefPubMedSearch in Google Scholar
  • 3 Besarab A, Bolton WK, Browne JK. et al. The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin. N Engl J Med 1998; 339: 584-590
    CrossrefPubMedSearch in Google Scholar
  • 4 Pfeffer MA, Burdmann EA, Chen C-Y. et al. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 2009; 361: 2019-2032
    CrossrefPubMedSearch in Google Scholar
  • 5 KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279
    Crossref
  • 6 Collister D, Komenda P, Hiebert B. et al. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 472
    CrossrefPubMedSearch in Google Scholar
  • 7 Wright DG, Wright EC, Narva AS. et al. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. CJASN 2015; 10: 1822-1830
    CrossrefPubMedSearch in Google Scholar
  • 8 Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci 2009; 66: 3539-3554
    CrossrefPubMedSearch in Google Scholar
  • 9 Epstein ACR, Gleadle JM, McNeill LA. et al. C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation. Cell 2001; 107: 43-54
    CrossrefPubMedSearch in Google Scholar
  • 10 Bernhardt WM, Wiesener MS, Scigalla P. et al. Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD. JASN 2010; 21: 2151-2156
    CrossrefPubMedSearch in Google Scholar
  • 11 Hasegawa S, Tanaka T, Nangaku M. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. Current Opinion in Nephrology and Hypertension 2018; 27: 331-338
    CrossrefPubMedSearch in Google Scholar
  • 12 Locatelli F, Minutolo R, De Nicola L. et al. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors. Drugs 2022; 82: 1565-1589
    CrossrefPubMedSearch in Google Scholar
  • 13 Brookhart MA, Schneeweiss S, Avorn J. et al. The Effect of Altitude on Dosing and Response to Erythropoietin in ESRD. J Am Soc Nephrol 2008; 19: 1389-1395
    CrossrefPubMedSearch in Google Scholar
  • 14 Brookhart MA, Bradbury BD, Avorn J. et al. The Effect of Altitude Change on Anemia Treatment Response in Hemodialysis Patients. Am J Epidemiol 2011; 173: 768-777
    CrossrefPubMedSearch in Google Scholar
  • 15 Flamme I, Oehme F, Ellinghaus P. et al. Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85–3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects. PLoS ONE 2014; 9: e111838
    CrossrefPubMedSearch in Google Scholar
  • 16 Zhang Y, Thamer M, Stefanik K. et al. Epoetin requirements predict mortality in hemodialysis patients. American Journal of Kidney Diseases 2004; 44: 866-876
    CrossrefSearch in Google Scholar
  • 17 Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-1634
    CrossrefPubMedSearch in Google Scholar
  • 18 Santos EJF, Dias RSC, Lima JFDB. et al. Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives. Int J Nephrol Renovasc Dis 2020; 13: 231-237
    CrossrefPubMedSearch in Google Scholar
  • 19 Zhao X-N, Liu S-X, Wang Z-Z. et al. Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria. Eur J Med Res 2023; 28: 230
    CrossrefPubMedSearch in Google Scholar
  • 20 Wei S, Sun J, Xu K. et al. Safety and effectiveness of recombinant human erythropoietin coupled with different doses of Roxadustat for treatment of renal anemia in patients on maintenance hemodialysis. Am J Transl Res 2023; 15: 5120-5128
    PubMedSearch in Google Scholar
  • 21 Hou Y-P, Wang C, Mao X-Y. et al. Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis. J Formos Med Assoc 2022; 121: 2288-2299
    CrossrefPubMedSearch in Google Scholar
  • 22 Nemeth E, Tuttle MS, Powelson J. et al. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science 2004; 306: 2090-2093
    CrossrefPubMedSearch in Google Scholar
  • 23 Schwartz AJ, Das NK, Ramakrishnan SK. et al. Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload. J Clin Invest 2018; 129: 336-348
    CrossrefPubMedSearch in Google Scholar
  • 24 Nakai T, Saigusa D, Kato K. et al. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction. Life Sci 2024; 346: 122641
    CrossrefPubMedSearch in Google Scholar
  • 25 Schwartz AJ, Das NK, Ramakrishnan SK. et al. Hepatic hepcidin/intestinal HIF-2α axis maintains iron absorption during iron deficiency and overload. J Clin Invest 2018; 129: 336-348
    CrossrefPubMedSearch in Google Scholar
  • 26 Nakornchai P, Jitraree A, Homjan MC. et al. Comparison of citrate dialysate in pre- and post-dilution online hemodiafiltration: effect on clot formation and adequacy of dialysis in hemodialysis patients. Ren Fail 2024; 46: 2302109
    CrossrefPubMedSearch in Google Scholar
  • 27 Fishbane S, El-Shahawy MA, Pecoits-Filho R. et al. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. JASN 2021; 32: 737-755
    CrossrefPubMedSearch in Google Scholar
  • 28 Shutov E, Sułowicz W, Esposito C. et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant 2021; 36: 1629-1639
    CrossrefPubMedSearch in Google Scholar
  • 29 Coyne DW, Roger SD, Shin SK. et al. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep 2021; 6: 624-635
    CrossrefPubMedSearch in Google Scholar
  • 30 Fishbane S, Pollock CA, El-Shahawy M. et al. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. J Am Soc Nephrol 2022; 33: 850-866
    CrossrefPubMedSearch in Google Scholar
  • 31 Charytan C, Manllo-Karim R, Martin ER. et al. A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study. Kidney Int Rep 2021; 6: 1829-1839
    CrossrefPubMedSearch in Google Scholar
  • 32 Provenzano R, Shutov E, Eremeeva L. et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant 2021; 36: 1717-1730
    CrossrefPubMedSearch in Google Scholar
  • 33 Barratt J, Andric B, Tataradze A. et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant 2021; 36: 1616-1628
    CrossrefPubMedSearch in Google Scholar
  • 34 Wu H, Cheng H, Wang C. et al. Roxadustat and Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease: A Randomized, Open-Label, Phase 4 Study (ALTAI). Adv Ther 2024; 41: 1168-1183
    CrossrefPubMedSearch in Google Scholar
  • 35 Chen N, Hao C, Liu B-C. et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med 2019; 381: 1011-1022
    CrossrefPubMedSearch in Google Scholar
  • 36 Akizawa T, Iwasaki M, Yamaguchi Y. et al. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. J Am Soc Nephrol 2020; 31: 1628-1639
    CrossrefPubMedSearch in Google Scholar
  • 37 Tu Y, Li Z-L, Liu H. et al. Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study. Kidney Dis 2024; 10: 193-199
    CrossrefPubMedSearch in Google Scholar
  • 38 Eckardt K-U, Agarwal R, Aswad A. et al. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med 2021; 384: 1601-1612
    CrossrefPubMedSearch in Google Scholar
  • 39 Chertow GM, Pergola PE, Farag YMK. et al. Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD. N Engl J Med 2021; 384: 1589-1600
    CrossrefPubMedSearch in Google Scholar
  • 40 Toka HR, Bernardo M, Burke SK. et al. Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD. Am J Kidney Dis 2024; Nov 7 S0272–6386(24)01043–6
    CrossrefPubMedSearch in Google Scholar
  • 41 Singh AK, Carroll K, Perkovic V. et al. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med 2021; 385: 2325-2335
    CrossrefPubMedSearch in Google Scholar
  • 42 Singh AK, Carroll K, McMurray JJV. et al. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med 2021; 385: 2313-2324
    CrossrefPubMedSearch in Google Scholar
  • 43 Singh AK, Cizman B, Carroll K. et al. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med 2022; 182: 592
    CrossrefPubMedSearch in Google Scholar
  • 44 Johansen KL, Cobitz AR, Singh AK. et al. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int 2023; 103: 1180-1192
    CrossrefPubMedSearch in Google Scholar
  • 45 GSK Quartalsbericht Q2 22023. Im Internet: Accessed February 12, 2025 at: https://www.gsk.com/media/10423/q2–2023-results-announcement.pdf
  • 46 Harris AL. Hypoxia — a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47
    CrossrefPubMedSearch in Google Scholar
  • 47 Fachinformation Evrenzo. Im Internet: Accessed February 13, 2025 at: https://www.fachinfo.de/fi/detail/023490/evrenzotm-20-mg-50-mg-70-mg-100-mg-150-mg-filmtabletten
  • 48 Fachinformation Vafseo. Im Internet: Accessed February 13, 2025 at: https://fachinfo.de/fi/pdf/024288/vafseo-r-150-mg-300-mg-450-mg-filmtabletten